Piramal Pharma Solutions has announced a strategic partnership with Ajinomoto Bio-Pharma Services to enhance their antibody-drug conjugate (ADC) development and manufacturing capabilities, offering innovative solutions to clients globally.

BioDlink has been awarded 'Emerging CDMO of the Year,' recognizing its innovation in biologics and ADC development through advanced technology and quality systems.

Mycenax Biotech has signed a licensing agreement with RIN Institute to utilize its proprietary linker technology. This partnership aims to accelerate ADC development and offers enhanced therapeutic solutions.

Mycenax Biotech Inc. and Japan's RIN Institute team up through a license agreement to utilize innovative linker technology for developing advanced ADCs.

Piramal Pharma Solutions has announced a strategic partnership with IntoCell to expand its bioconjugate capabilities, leveraging innovative payload-linker technologies.

Piramal Pharma Solutions has established a partnership with IntoCell to enhance its bioconjugate capabilities and expedite drug development efforts.

Syngene International is set to enhance its services with a new GMP bioconjugation suite, facilitating end-to-end antibody-drug conjugate development. This expansion will streamline drug development processes for biotech clients.

Mycenax Biotech Inc. and SPERA PHARMA Inc. have joined forces to enhance the production services of antibody-drug conjugates, streamlining development for biopharmaceutical companies.

WuXi XDC and LigaChem Biosciences have enhanced their collaboration with a new MOU to accelerate the development of next-gen ADC therapies, improving treatment options for cancer patients.

DAAN Biotherapeutics has signed an exclusive licensing agreement with LigaChem Biosciences to enhance antibody-drug conjugate (ADC) therapeutic development.

Samsung Biologics announces the extension of its collaboration with LigaChem Biosciences to enhance antibody-drug conjugate (ADC) development services.